CEO Executive AssistantInsurance product development is one of the most complex operational functions a carrier manages. It requires coordinated expertise from actuarial, legal, compliance, distribution, and technology teams, spans regulatory approval timelines that can stretch twelve to eighteen months, and carries financial exposure that demands rigorous governance. For that reason, many insurance CEOs hold product development too close, believing the complexity justifies their direct involvement.
Delegation for insurance product development is not about reducing rigor. It is about putting the right decisions in front of the right people at every stage, so that your organization moves faster, your teams develop genuine product expertise, and your own capacity is reserved for the strategic decisions that genuinely require the CEO.
This article gives you the delegation architecture to achieve that outcome: how to structure stage-gate authority, assign regulatory approval workflow ownership, and build the governance model that keeps you appropriately informed without making you a bottleneck.
Why Delegation for Insurance Product Development Requires a Stage-Gate Model
Product development in insurance does not move in a straight line. It advances through discrete phases, each with its own outputs, decision criteria, and approval requirements. The stage-gate model, a structured review process where each development phase ends with a formal evaluation before proceeding to the next, is the natural framework for organizing delegation authority.
Without a stage-gate model, CEOs face a difficult choice: stay deeply involved throughout the development process (which consumes enormous time and creates a single point of failure), or delegate broadly without clear authority boundaries (which creates coordination failures and inconsistent quality). The stage-gate model resolves this dilemma by specifying exactly who has authority at each phase transition.
McKinsey’s research on product development governance consistently shows that organizations with clear stage-gate governance outperform peers on development cycle time and product launch success rates. In insurance, where regulatory timelines are non-negotiable, faster internal decision-making is one of the few levers that actually compresses the overall product-to-market timeline.
The Four Stages of Insurance Product Development
A workable stage-gate framework for insurance product development organizes around four phases:
Stage 1: Concept and feasibility. Defining the product concept, assessing market need, evaluating competitive positioning, and conducting a preliminary feasibility review from actuarial and regulatory perspectives.
Stage 2: Design and development. Building the product structure: coverage terms, exclusions, pricing architecture, form language, and distribution model. This stage ends with a complete product specification.
Stage 3: Regulatory submission and approval. Preparing and filing all required regulatory materials, managing the state insurance department review process, responding to objections and information requests, and obtaining all required approvals before launch.
Stage 4: Launch and post-launch review. Coordinating distribution rollout, training, marketing materials, and first-period performance monitoring.
Each stage-gate has a defined owner, a defined set of exit criteria, and a defined escalation threshold. Your job as CEO is to approve the delegation framework, chair the Stage 2 and Stage 4 gate reviews for significant products, and receive summary reporting on Stage 1 and Stage 3 activity.
Delegating Stage 1 Authority to Product Managers
Your product managers own Stage 1 entirely. Their delegated authority at this stage includes: approving new product concepts for feasibility analysis, commissioning preliminary market research and competitive reviews, and requesting preliminary actuarial assessment.
What you should not be doing at Stage 1: evaluating individual product concepts, approving feasibility studies, or reviewing competitive analysis documents. Your involvement at this stage should be limited to receiving a monthly pipeline summary that shows which concepts are in Stage 1, their development timeline, and the preliminary feasibility verdict.
The Stage 1 gate decision, the determination of whether a concept advances to full design and development, should be made by your Chief Product Officer or VP of Product, in consultation with your Chief Actuary and General Counsel. Only concepts with unusually large financial exposure or significant strategic deviation should require CEO approval at Stage 1.
Build this explicitly into your authority matrix. Write it down. Communicate it to the product team. The goal is to remove yourself from early-stage concept evaluation so that your team develops the judgment to assess product viability independently.
Delegating Stage 2 Authority to Product and Actuarial Teams
Stage 2 is where product development consumes the most organizational energy. Building product specifications, drafting form language, developing pricing models, and structuring distribution terms requires sustained collaboration between product management and actuarial teams. This collaboration should happen without CEO involvement.
Actuarial Authority in Product Design
Your Chief Actuary and their team own the pricing architecture and loss cost modeling in Stage 2. Delegate to them the authority to: approve pricing methodologies for new products, sign off on loss cost assumptions used in the product specification, and determine the actuarial inputs to the regulatory filing package.
Do not review actuarial pricing models personally. Do not hold approval authority over loss cost assumptions. Your role is to trust the judgment of your Chief Actuary on technical pricing questions, intervening only when the actuarial team flags a pricing assumption that carries material financial risk beyond their own authority threshold.
Build a clear escalation threshold into the Chief Actuary’s authority: any pricing scenario with modeled loss ratio exposure beyond a defined threshold (for example, greater than five points above the target loss ratio) requires CEO awareness before the product proceeds through Stage 2.
Product Manager Authority in Specification Development
Your product managers own the coverage terms, form language structure, and distribution model within Stage 2. Their delegated authority includes: approving coverage scope decisions within defined parameters, coordinating with legal and compliance on form language, and recommending the distribution channel strategy for new products.
The Stage 2 gate review, the approval to advance a product specification to regulatory submission, is one of the two reviews where CEO presence adds genuine value. Attend this review for significant product launches. Your role at this review is strategic: Does this product fit our portfolio strategy? Does the risk profile match our appetite? Are we resourced to support the regulatory submission and distribution launch? Leave the technical review to your Chief Actuary and VP of Product.
Delegating Regulatory Approval Workflow Ownership
Regulatory submissions are the most time-critical element of insurance product development and the area where poor delegation creates the most significant delays. The regulatory approval workflow needs a single owner with clear authority to manage the state insurance department relationship without constant escalation.
Assigning the Regulatory Owner
Your VP of Regulatory Affairs or Regulatory Counsel owns the regulatory submission and approval workflow entirely. Their delegated authority includes: signing and submitting all state insurance department filings (where state law permits non-CEO signature), managing all departmental correspondence and information requests, negotiating form objections and coverage language disputes, and tracking multi-state approval status across all active submissions.
Many insurance CEOs are surprised to learn how much of the regulatory approval workflow can be fully delegated. State insurance departments work primarily with regulatory counsel and compliance officers. CEO involvement in routine submission management signals a governance gap, not engagement. Your regulatory owner should be authorized to manage this process from submission to approval with no CEO touchpoints on routine filings.
Escalation Criteria for Regulatory Issues
Define the specific circumstances that require CEO involvement in the regulatory process. A workable escalation framework: the regulatory owner escalates to the CEO when a state insurance department issues a market conduct concern (not a technical form objection), when a submission is denied and the denial creates material strategic risk, or when a regulatory relationship issue requires executive-level engagement with a Commissioner’s office.
Routine form objections, standard information requests, and timeline extensions do not require CEO involvement. Trust your regulatory team to handle these. A clear escalation protocol gives them the confidence to operate independently while ensuring you are informed when the situation genuinely warrants it.
Multi-State Filing Coordination
For carriers operating in multiple states, coordinating parallel regulatory submissions is a significant operational complexity. Delegate this coordination to your regulatory owner and support it with a tracking system that gives you visibility without involvement. A weekly status dashboard showing active filings, expected approval timelines, and any states with open objections is sufficient for CEO-level monitoring.
Your executive assistant can maintain this dashboard and flag items that meet your escalation criteria. Thoughtful EA-assisted tracking keeps your regulatory pipeline visible without pulling you into the details.
Stage 4 Delegation: Launch and Post-Launch Monitoring
Product launch is another area where CEOs often over-involve themselves. The launch execution, including distribution training, marketing material deployment, and agent/broker communication, is fully delegatable to your product team and distribution leadership.
Assign the product launch owner explicitly. This person, typically your VP of Product or Chief Distribution Officer, is responsible for launch readiness, launch execution, and first-period monitoring. Their delegated authority includes approving all launch materials, signing off on distribution training content, and presenting the 90-day post-launch performance report.
Your role at launch: approve the go/no-go decision at the Stage 4 gate review for significant new products, receive the 90-day post-launch report, and participate in the annual product portfolio review where launch performance is evaluated against projections.
Building the Product Development Governance Report
Delegation for insurance product development requires a governance structure that keeps you informed at the portfolio level. Design a monthly product development report that your Chief Product Officer prepares and delivers:
The report should cover: active products by stage, stage-gate decisions made in the prior month, regulatory submission status and anticipated approval timelines, any escalations that occurred and how they were resolved, and the pipeline of concepts in Stage 1 evaluation.
This single report, reviewed monthly, gives you complete portfolio visibility without operational involvement. Pair it with a quarterly product strategy session where you and your product leadership team review the pipeline against market positioning, competitive dynamics, and capital allocation priorities.
Consider pairing your governance structure with proven delegation principles that apply across every function you are managing.
Delegation for insurance product development is an investment in your organization’s innovation capacity. When your product managers and actuarial teams have clear authority to move products through development stages, they build expertise, move faster, and produce better products. When your regulatory team owns the approval workflow without constant escalation, submissions are managed professionally and state relationships are stronger. And when you reserve your involvement for the stage-gate reviews and strategic decisions that genuinely require your judgment, you lead more effectively across every dimension of your carrier’s performance.